Loading...

Brilliant Violet 605™ anti-mouse CD45.1 Antibody

Pricing & Availability
Clone
A20 (See other available formats)
Regulatory Status
RUO
Other Names
T200, Ly-5.1, LCA
Isotype
Mouse (A.SW) IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
A20_BV605_051812
SJL mouse splenocytes were stained with CD45.1 (clone A20) Brilliant Violet 605™.
  • A20_BV605_051812
    SJL mouse splenocytes were stained with CD45.1 (clone A20) Brilliant Violet 605™.
Compare all formats See Brilliant Violet 605™ spectral data
Cat # Size Price Quantity Check Availability Save
110737 125 µL $220
Check Availability


Need larger quantities of this item?
Request Bulk Quote
110738 50 µg $297
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD45.1 is an alloantigen of CD45, expressed by Ly5.1 bearing mouse strains (e.g., RIII, SJL/J, STS/A, DA). CD45, a member of the protein tyrosine phosphatase (PTP) family, is a 180-240 kD glycoprotein expressed on all hematopoietic cells except mature erythrocytes and platelets. There are multiple isoforms in mice that play key roles in TCR and BCR signal transduction. These isoforms are very specific to the activation and maturation states of the cell as well as specific cell types. The primary ligands for CD45 are galectin-1, CD2, CD3, CD4, TCR, CD22, and Thy-1.

Product Details
Technical data sheet

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Mouse
Immunogen
SJL mouse thymocytes and splenocytes
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation
The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 605™ under optimal conditions.
Concentration
µg sizes: 0.2 mg/mL
µL sizes: lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For immunofluorescent staining using the µg size, the suggested use of this reagent is ≤0.5 µg per million cells in 100 µl volume. For immunofluorescent staining using the µl size, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

Brilliant Violet 605™ excites at 405 nm and emits at 603 nm. The bandpass filter 610/20 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel. Refer to your instrument manual or manufacturer for support. Brilliant Violet 605™ is a trademark of Sirigen Group Ltd.


Learn more about Brilliant Violet™.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.
Excitation Laser
Violet Laser (405 nm)
Application Notes

The A20 antibody does not react with leukocytes or mouse cells expressing the CD45.2 alloantigen. Additional reported applications (for relevant formats of this clone) include: immunoprecipitation3, in vitro blocking of B cell responses1,2, immunohistochemical staining of frozen sections: OCT embedded7 and acetone-fixed4-6 (direct immunofluorescence detection with fluorochrome conjugated A20 was used in (5) and (6)).

Application References

(PubMed link indicates BioLegend citation)
  1. Yakura H, et al. 1983. J. Exp. Med. 157:1077. (Block)
  2. Yakura H, et al. 1986. J. Immunol. 136:2729. (Block)
  3. Shen FW, et al. 1986. Immunogenetics 24:146. (IP)
  4. Suzuki K, et al. 2000. Immunity 13:691. (IHC-F)
  5. Werner N, et al. 2002. Arterioscler. Thromb. Vasc. Biol. 22:1567. (IHC-F)
  6. Lessner SM, et al. 2002. Am. J. Pathol. 160:2145. (FC, IHC-F)
  7. Chen CC, et al. 2005. P. Natl. Acad. Sci. USA 102:11408 (IHC-F)
  8. Pascal V, et al. 2007. J. Immunol. 179:1751. (FC)
  9. Mende I, et al. 2006. Blood 107:1383. (IHC-F, FC)
  10. Phan TG, et al. 2007. Nature Immunol. 8:992. (FC)
  11. Wither DR, et al. 2009. J. Immunol. 183:5079. PubMed
  12. Pascal V, et al.2007. J. Immunol. 179:1751. PubMed
  13. Lee SW, et al. 2009. J. Immunol. 182:6753. PubMed
  14. Takada K, et al. 2009. J. Exp Med. 206:2253. PubMed
  15. Beamer CA, et al. 2007. Am. J. Respir. Cell. Mol. Biol. 37:729. (FC) PubMed
  16. Li LX, et al. 2010. J. Immunol. 184:1728. PubMed
  17. Hosoi A, et al. 2008. Cancer Res. 68:3941. (FC) PubMed
  18. Kenna TJ, et al. 2008. Blood 111:2091. PubMed
  19. Kohlmeier JE, et al. 2008. Immunity. 29:101. (FC) PubMed
Product Citations
  1. Kuczynski EA, et al. 2022. EMBO Mol Med. 14:e15816. PubMed
  2. Hu Q, et al. 2022. Cell Rep. 40:111035. PubMed
  3. Roy IM, et al. 2022. iScience. 25:105171. PubMed
  4. Scherer S, et al. 2023. Nat Immunol. 24:501. PubMed
  5. Krummey SM, et al. 2020. Cell Reports. 30(5):1282-1291.e5.. PubMed
  6. Han SJ et al. 2017. Immunity. 47(6):1154-1168 . PubMed
  7. Van Den Eeckhout B, et al. 2020. NPJ Vaccines. 5:64. PubMed
  8. Shen Y, et al. 2021. Comput Struct Biotechnol J. 19:5360. PubMed
  9. Cannons JL, et al. 2021. Cell Rep. 37:109804. PubMed
  10. Hu W, et al. 2021. Nat Immunol. 22:1163. PubMed
  11. Delacher M, et al. 2021. Immunity. 54(4):702-720.e17. PubMed
  12. Chow MT et al. 2019. Immunity. 50(6):1498-1512 . PubMed
  13. Sugimoto C, et al. 2022. Elife. 11:. PubMed
  14. Wang H, et al. 2022. Curr Protoc. 2:e446. PubMed
  15. Lu SX, et al. 2021. Cell. . PubMed
  16. Cunningham C, et al. 2016. PLoS Pathog. 12: 1005356. PubMed
  17. Lam WY et al. 2018. Cell reports. 24(9):2479-2492 . PubMed
  18. Duan L, et al. 2021. Immunity. 54:2256. PubMed
  19. Wagner JA, et al. 2020. Cell Rep. 31:107720. PubMed
  20. Leonard JD et al. 2017. Immunity. 47(1):107-117 . PubMed
  21. Glaros V, et al. 2021. Immunity. 54:2005. PubMed
  22. He Y, et al. 2021. Cell Metabolism. 33(5):988-1000.e7. PubMed
  23. Mansell E, et al. 2020. Cell Stem Cell. . PubMed
  24. Sinha SR, et al. 2020. Cell Host Microbe. 27:659. PubMed
  25. Frost JN, et al. 2021. Med (N Y). 2:164. PubMed
  26. Murakami K, et al. 2021. Cell Reports. 34(1):108579. PubMed
  27. Morris AB, et al. 2020. Immunity. 52(1):136-150.e6.. PubMed
  28. Crauste F, et al. 2017. Cell Syst. 0.379166667. PubMed
  29. Engblom C, et al. 2017. Science. 358:6367. PubMed
  30. Zhang H, et al. 2021. Cell Reports. 35(6):109096. PubMed
  31. Celik H, et al. 2018. Cancer Cell. 34:741. PubMed
  32. Xu C, et al. 2020. Immunity. 53(2):417-428.e4. PubMed
  33. Van Den Eeckhout B, et al. 2020. NPJ Vaccines. 0.252777778. PubMed
  34. Pai CS, et al. 2020. Immunity. 50(2):477-492. PubMed
  35. Bosteels C, et al. 2020. Immunity. 52(6):1039-1056.e9.. PubMed
  36. Rivera CA, et al. 2022. Immunity. 55:129. PubMed
  37. Zhang J, et al. 2021. Stem Cell Res Ther. 12:579. PubMed
RRID
AB_2562565 (BioLegend Cat. No. 110737)
AB_2562565 (BioLegend Cat. No. 110738)

Antigen Details

Structure
Protein tyrosine phosphatase (PTP) family, 180-240 kD
Distribution

All hematopoietic cells except mature erythrocytes and platelets of the CD45.1 strain of mice

Function
Phosphatase, T and B cell activation
Ligand/Receptor
Galectin-1, CD2, CD3, CD4
Biology Area
Cell Biology, Immunology, Inhibitory Molecules, Neuroscience, Neuroscience Cell Markers
Molecular Family
CD Molecules
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Trowbridge IS, et al. 1993. Annu. Rev. Immunol. 12:85.
3. Kishihara K, et al. 1993. Cell 74:143.
4. Pulido R, et al. 1988. J. Immunol. 140:3851.

Gene ID
19264 View all products for this Gene ID
Specificity (DOES NOT SHOW ON TDS):
CD45.1
Specificity Alt (DOES NOT SHOW ON TDS):
CD45.1
App Abbreviation (DOES NOT SHOW ON TDS):
FC
UniProt
View information about CD45.1 on UniProt.org
Go To Top Version: 2    Revision Date: 10/21/2013

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login/Register
Remember me
Forgot your password? Reset Password
Request an Account